Pembrolizumab for the Treatment of Refractory or Relapsed Thymic Epithelial Tumors: Review of the NCT02607631 Study

No content published by the Journal of Evidence-Based Medicine may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journal without permission.

All articles published represent the opinions of the authors, and do not reflect the official policy of the Journal of Evidence-Based Medicine’ Sponsors or the Editorial Board, unless this is clearly specified.